abs265.txt	current	strategies	aimed	to	cure	hiv	infection	are	based	on	combined	efforts	toreactivate	the	virus	from	latency	and	improve	immune	effector	cell	function	toclear	infected	cells		these	primarily	focused	cd8+	t	andapproaches	challenging	due	insufficient	antigen	production	frominfected	poor	hiv-specific	γδ	represent	a	uniquesubset	of	that	can	traffic	tissues	selectively	targetcancer	or	virally	without	requiring	mhc	presentation	we	analyzedwhether	complementary/alternative	immunotherapeuticapproach	towards	hiv-infected	virologicallysuppressed	donors	were	expanded	with	bisphosphonate	pamidronate	(pam)	cellswere	used	in	autologous	cellular	systems	ex	vivo	(a)	potentcytotoxic	effectors	able	efficiently	inhibit	replication	(b)degranulate	presence	cd4+	(c)specifically	clear	latently	after	reversal	withvorinostat	this	is	first	proof	concept	our	knowledge	showing	tcells	target	reservoirs	upon	ourresults	open	potentially	new	insights	into	immunotherapeutic	use	for	interventions	eradication
